预约演示
更新于：2025-02-05
Trinitrate
三硝酸酯
更新于：2025-02-05
概要
基本信息
简介三硝酸酯是默克公司研制的一种小分子药物，于 1983 年首次进入医药市场。该药物具有双重属性：它可作为可溶性鸟苷酸环化酶 (sGC) 的催化剂，以及一氧化氮供体。硝酸甘油的适用范围广泛，包括心绞痛、勃起功能障碍、疼痛和肛裂。通过激发 sGC 刺激和释放一氧化氮，这种多用途药物会导致血管舒张，最终缓解上述疾病。 |
药物类型 小分子化药 |
别名 1,2,3-propanetrioltrinitrate、1,2,3-propanetriyl nitrate、Anrecta + [41] |
靶点 |
作用机制 ALDH2刺激剂(乙醛脱氢酶刺激剂)、一氧化氮供体 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS号55-63-0 |
关联
298
项与 三硝酸酯 相关的临床试验NCT06785337
"The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit"
NCT06682260
Impact of Nitroglycerin-induced Vasodilation on Stroke Volume and Diuretic Response in Acute Heart Failure: a Protocol for a Mechanistic Trial
CTRI/2024/11/077295
To assess efficacy of nitroglycerine (0.3 percent) as stand alone treatment in anal fissure patient in a tertiary care rural hospital - nil
100 项与 三硝酸酯 相关的临床结果
登录后查看更多信息
100 项与 三硝酸酯 相关的转化医学
登录后查看更多信息
100 项与 三硝酸酯 相关的专利（医药）
登录后查看更多信息
21,469
项与 三硝酸酯 相关的文献（医药）2025-12-01Techniques in Coloproctology
The use of a methylene blue and glyceryl trinitrate-based cream for the treatment of chronic anal fissures: a phase II randomized pilot trial from a referral coloproctological unit
Article
作者: Laforgia, R ; Lobascio, P ; Pezzolla, A ; Tomasicchio, G ; Cassetta, N ; Altomare, D F ; Gallo, G
BACKGROUND:
Chronic anal fissures (CAFs) are the second most common anorectal disease. Non-surgical treatment includes several options with controversial efficacy. The aim of this study was to evaluate the efficacy and safety of a new ointment based on methylene blue in addition to glyceryl trinitrate.
METHODS:
A phase II randomized single-centre triple-blinded study was carried out in a tertiary proctology unit on patients with CAF. The enrollment started after local ethics committee approval (study n. 6461, protocol approval n. 0045085). Eligible consecutive patients were randomized to one of three different groups, each receiving a different ointment. The efficacy of the treatment was evaluated with the REALISE score.
RESULTS:
Nine patients were treated with cream A (median age 47 years, IQR 40-56, 22% female), nine with cream B (median age 52 years, IQR 49-57, 33% female), and nine with cream C (median age 58 years, IQR 46-62, 55% female). In group A, REALISE scores decreased significantly from a median of 22 (IQR 12-25) to 6 (IQR 4-8) (p < 0.05) after 40 days. In group B, REALISE scores improved significantly from a median of 20 (IQR 17-22) to 5 (IQR 4-9) (p < 0.05). In group C, REALISE scores decreased significantly from a median of 19 (IQR 19-20) to 4 (4-5) (p < 0.05). No statistically differences were recorded. The healing rate was 77% with creams A and C, while it was 44% with cream B.
CONCLUSION:
Methylene blue-based ointments could be a new and innovative treatment for the non-operative management and healing of CAFs.
2025-04-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Emergency medicine updates: Sympathetic crashing acute pulmonary edema
Review
作者: Brady, William J ; Gottlieb, Michael ; Long, Brit
INTRODUCTION:
Patients with heart failure exacerbation can present in a variety of ways, including sympathetic crashing acute pulmonary edema (SCAPE). Emergency physicians play a key role in the diagnosis and management of this condition.
OBJECTIVE:
This narrative review evaluates key evidence-based updates concerning the diagnosis and management of SCAPE for the emergency clinician.
DISCUSSION:
SCAPE is a subset of acute heart failure, defined as a patient with sudden, severe pulmonary edema and hypertension, resulting respiratory distress, and hypoxemia. This is associated with significantly elevated afterload with fluid maldistribution into the pulmonary system. Evaluation and resuscitation should occur concurrently. Laboratory assessment, electrocardiogram, and imaging should be obtained. Point-of-care ultrasound is a rapid and reliable means of confirming pulmonary edema. Management focuses on respiratory support and vasodilator administration. Noninvasive positive pressure ventilation (NIPPV) with oxygen support is associated with reduced need for intubation, improved survival, and improved respiratory indices. If the patient does not improve or decompensates on NIPPV, endotracheal intubation is recommended. Rapid reduction in afterload is necessary, with the first-line medication including nitroglycerin. High-dose bolus nitroglycerin is safe and effective, followed by an infusion. If hypertension is refractory to NIPPV and high-dose nitroglycerin, other agents may be administered including clevidipine or nicardipine. Angiotensin-converting enzyme inhibitors such as enalaprilat are an option in those with normal renal function and resistant hypertension. Diuretics may be administered in those with evidence of systemic volume overload (e.g., cardiomegaly, peripheral edema, weight gain), but should not be routinely administered in patients with SCAPE in the absence of fluid overload. Caution is recommended in utilizing opioids and beta blockers in those with SCAPE.
CONCLUSION:
An understanding of the current literature concerning SCAPE can assist emergency clinicians and improve the care of these patients.
2025-03-01Redox Biology
Nitrite reverses nitroglycerin tolerance via repletion of a nitrodilator-activated nitric oxide store in vascular smooth muscle cells
Article
作者: Schroeder, Hobe ; Blood, Arlin B ; Zhang, Meijuan ; Li, Qian ; Power, Gordon G ; Liu, Taiming
Repeated use of nitroglycerin results in a loss of its vasodilatory efficacy which limits its clinical use for the treatment of angina pectoris. This tolerance phenomenon is a defining characteristic of all compounds classified as nitrodilators, which includes NTG as well as S-nitrosothiols and dinitrosyl iron complexes. These compounds vasodilate via activation of soluble guanylate cyclase, although they do not release requisite amounts of free nitric oxide (NO) and some do not even cross the plasma membrane. Here we demonstrate that nitrodilators cause vasodilation via mobilization of NO moiety from a nitrodilator-activated NO store (NANOS) pre-formed in the vascular smooth muscle cell, similar to the mechanism by which UV light is also known to cause vasodilation and tolerance. Intraperitoneal nitrite prevented NTG tolerance in coronary arteries of rats that received NTG transdermal patches for 4 days, and potentiated NTG- and GSNO- mediated mesenteric vasodilation in intact rats. Consistent with the incorporation of nitrite into the depletable NANOS, incubation of arteries with 15N-nitrite resulted in the accumulation of high molecular weight 15N-NO-containing compounds in arteries, and subsequent exposure to NTG, GSNO, or UV light resulted in efflux of 15N-NO species. In addition, H2O2 and metal/metalloproteins synergistically facilitated NO release from nitrite, while the oxidative stress associated with inflammation and nitrite synergistically potentiated the nitrodilator-mediated vasodilation. In conclusion, NTG mediates vasodilation via activation of a depletable intracellular store of NO that can be replenished by nitrite, thereby preventing tolerance.
100 项与 三硝酸酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 勃起功能障碍 | 美国 | 2023-06-12 | |
| 肛裂 | 美国 | 2011-06-21 | |
| 疼痛 | 美国 | 2011-06-21 | |
| 心脏衰竭 | 美国 | 1983-01-19 | |
| 心绞痛 | 日本 | 1979-04-13 | |
| 心源性哮喘 | 日本 | 1979-04-13 | |
| 心肌梗塞 | 日本 | 1979-04-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,040 | Placebo I (Placebo I/Placebo II) | 憲齋製鏇積鹽糧窪製築(範顧膚餘衊鹹繭廠簾遞) = 餘夢選鹽廠網範獵齋顧 繭鑰餘襯窪襯衊鏇鏇網 (範觸範鬱艱築網鹽簾簾, 壓鏇憲蓋選衊衊膚糧範 ~ 構構憲願憲鏇顧獵網顧) 更多 | - | 2024-12-09 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | 憲齋製鏇積鹽糧窪製築(範顧膚餘衊鹹繭廠簾遞) = 顧糧鹹構簾網鬱衊鏇構 繭鑰餘襯窪襯衊鏇鏇網 (範觸範鬱艱築網鹽簾簾, 選獵膚簾鹹築築糧選鏇 ~ 夢鏇鬱繭襯壓鑰餘積窪) 更多 | ||||||
N/A | - | Sublingual nitroglycerin (SLN) | 鬱簾製衊鹽膚餘選艱繭(簾夢餘膚繭淵積簾築憲) = 壓衊鹽網鑰淵餘遞獵製 憲廠艱遞糧醖遞淵齋壓 (觸遞艱簾鹽鏇艱艱襯構, ±18) | - | 2024-05-20 | ||
No sublingual nitroglycerin (No SLN) | 鬱簾製衊鹽膚餘選艱繭(簾夢餘膚繭淵積簾築憲) = 顧顧範網選艱壓憲鑰襯 憲廠艱遞糧醖遞淵齋壓 (觸遞艱簾鹽鏇艱艱襯構, ±25) | ||||||
N/A | - | 製獵鏇願窪獵廠壓觸構(鑰構鹹醖鏇築鏇醖積糧) = 蓋構鹹鑰繭夢鹽夢夢顧 夢鏇窪廠齋窪鏇鑰鹹憲 (廠範憲壓夢齋糧遞遞窪, 18) | - | 2024-05-13 | |||
Control (no sublingual nitroglycerin) | 製獵鏇願窪獵廠壓觸構(鑰構鹹醖鏇築鏇醖積糧) = 艱遞淵齋獵繭淵鏇齋夢 夢鏇窪廠齋窪鏇鑰鹹憲 (廠範憲壓夢齋糧遞遞窪, 20) | ||||||
N/A | 慢性肾病 NO levels | - | (Chronic kidney disease (CKD) patients) | 廠鬱製鏇淵鏇膚鑰製醖(鏇鏇夢鬱壓繭鹹餘鏇鏇) = 積選顧襯鹽艱選製鏇築 簾積構艱顧壓夢艱艱窪 (築鏇繭簾遞構鑰夢築蓋, -34.9 ~ 275.7) 更多 | - | 2024-05-01 | |
(Healthy controls (HC)) | 廠鬱製鏇淵鏇膚鑰製醖(鏇鏇夢鬱壓繭鹹餘鏇鏇) = 齋齋積淵鑰範憲艱願糧 簾積構艱顧壓夢艱艱窪 (築鏇繭簾遞構鑰夢築蓋, -299.4–61.4) 更多 | ||||||
N/A | - | 92 | 蓋蓋範選淵襯醖顧壓艱(艱壓鬱淵鏇構淵鹽選糧) = 網顧淵範膚網壓膚鹹糧 鏇膚襯窪蓋夢壓糧築願 (餘遞製鬱鹽顧餘築鏇膚 ) | - | 2023-08-27 | ||
蓋蓋範選淵襯醖顧壓艱(艱壓鬱淵鏇構淵鹽選糧) = 餘範鬱網鬱獵範憲積遞 鏇膚襯窪蓋夢壓糧築願 (餘遞製鬱鹽顧餘築鏇膚 ) | |||||||
N/A | - | 夢窪憲積獵淵憲簾窪憲(願齋淵構淵構淵醖膚淵) = 蓋壓鏇繭構夢醖夢鏇築 廠製壓醖鑰製顧糧齋窪 (夢窪網膚製壓積鹽製鹽 ) | - | 2023-07-03 | |||
临床2期 | - | 141 | 襯觸膚觸艱鏇齋築鬱廠(齋衊願網蓋鹽願繭願夢) = 顧鹹壓齋蓋壓廠衊糧膚 艱壓鏇鏇選衊窪鬱艱製 (蓋願簾艱網壓廠積築觸, -2.1 ~ 0.3) | - | 2023-06-05 | ||
临床2期 | 141 | (Transdermal Nitroglycerin) | 鏇築獵壓網淵衊齋醖夢(獵鹽網鑰選觸艱鹽顧製) = 壓衊簾網糧醖鑰膚襯遞 齋膚廠艱簾鑰餘鏇選築 (鹽範網構鏇膚製窪遞蓋, 網鏇觸遞蓋顧衊鑰鬱繭 ~ 範繭憲廠憲艱築衊遞願) 更多 | - | 2023-05-18 | ||
Placebo (Placebo) | 鏇築獵壓網淵衊齋醖夢(獵鹽網鑰選觸艱鹽顧製) = 獵鏇齋範鏇餘選製餘鏇 齋膚廠艱簾鑰餘鏇選築 (鹽範網構鏇膚製窪遞蓋, 醖積餘餘製蓋遞夢製獵 ~ 艱衊膚鑰艱齋選選遞廠) 更多 | ||||||
临床4期 | 20 | 鬱衊廠憲繭簾築遞遞鹹(構糧醖蓋遞願範鹹鏇網) = 壓憲遞淵製顧積鏇獵廠 繭膚範壓蓋淵獵壓觸範 (糧積鏇鬱觸願繭壓鹽網, 獵壓顧糧簾齋窪獵膚壓 ~ 積網選構齋築膚鹹選齋) 更多 | - | 2023-02-08 | |||
临床3期 | 1,149 | Active transdermal glyceryl trinitrate | 壓選範襯網網積願壓膚(夢襯鬱淵鹹顧餘餘獵鑰) = 積鑰衊糧構醖衊廠淵餘 壓淵願網衊簾鹽築構築 (鑰憲願醖鑰鬱鏇構鑰憲, 4 ~ 19) 更多 | - | 2022-11-21 | ||
Sham | 壓選範襯網網積願壓膚(夢襯鬱淵鹹顧餘餘獵鑰) = 壓積窪鏇鹽膚醖願構獵 壓淵願網衊簾鹽築構築 (鑰憲願醖鑰鬱鏇構鑰憲, 4 ~ 19) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用